Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 24390670)

1.

Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.

Hamada S, Urakawa H, Kozawa E, Futamura N, Ikuta K, Shimoyama Y, Nakamura S, Ishiguro N, Nishida Y.

Tumour Biol. 2014 May;35(5):4561-6. doi: 10.1007/s13277-013-1600-7. Epub 2014 Jan 5.

PMID:
24390670
2.

CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.

Hamada S, Futamura N, Ikuta K, Urakawa H, Kozawa E, Ishiguro N, Nishida Y.

PLoS One. 2014 May 1;9(5):e96391. doi: 10.1371/journal.pone.0096391. eCollection 2014.

3.

Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.

Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, Gronchi A, Bertario L, Pierotti MA, Pilotti S.

Clin Cancer Res. 2007 Sep 1;13(17):5034-40. Erratum in: Clin Cancer Res. 2008 Jul 1;14(13):4354.

4.

Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study.

Nishida Y, Tsukushi S, Shido Y, Wasa J, Ishiguro N, Yamada Y.

J Clin Oncol. 2010 Feb 20;28(6):e107-9. doi: 10.1200/JCO.2009.25.5950. Epub 2009 Dec 21. No abstract available.

5.

Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.

Amary MF, Pauwels P, Meulemans E, Roemen GM, Islam L, Idowu B, Bousdras K, Diss TC, O'Donnell P, Flanagan AM.

Am J Surg Pathol. 2007 Sep;31(9):1299-309.

PMID:
17721184
7.

Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.

Matono H, Oda Y, Nakamori M, Tamiya S, Yamamoto H, Yokoyama R, Saito T, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2008 Dec;39(12):1802-8. doi: 10.1016/j.humpath.2008.05.005. Epub 2008 Aug 19.

PMID:
18715618
8.

The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.

Liu JF, Zhang SW, Jamieson GG, Zhu GJ, Wu TC, Zhu TN, Shan BE, Drew PA.

Int J Cancer. 2008 Apr 1;122(7):1639-44.

PMID:
18058818
9.

beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours.

Saito T, Oda Y, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, Tsuneyoshi M.

J Pathol. 2001 Sep;195(2):222-8.

PMID:
11592102
10.

Abnormalities of the Wnt/β-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between β-catenin widespread nuclear expression and VEGF overexpression.

Matono H, Tamiya S, Yokoyama R, Saito T, Iwamoto Y, Tsuneyoshi M, Oda Y.

Histopathology. 2011 Sep;59(3):368-75. doi: 10.1111/j.1365-2559.2011.03945.x.

PMID:
22034877
11.

β-Catenin mutation status and outcomes in sporadic desmoid tumors.

Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, Szymonifka J, Yeap BY, Chen YL, Harmon DC, Choy E, Yoon SS, Raskin KA, Hornicek FJ, Nielsen GP.

Oncologist. 2013;18(9):1043-9. doi: 10.1634/theoncologist.2012-0449. Epub 2013 Aug 19.

12.
13.

FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center.

Colombo C, Foo WC, Whiting D, Young ED, Lusby K, Pollock RE, Lazar AJ, Lev D.

Histol Histopathol. 2012 May;27(5):641-9.

PMID:
22419028
14.

Analysis of APC, alpha-, beta-catenins, and N-cadherin protein expression in aggressive fibromatosis (desmoid tumor).

Ferenc T, Wroński JW, Kopczyński J, Kulig A, Sidor M, Stalińska L, Dziki A, Sygut J.

Pathol Res Pract. 2009;205(5):311-24. doi: 10.1016/j.prp.2008.11.002. Epub 2009 Jan 4.

PMID:
19124205
15.

Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice.

Jiang X, Li H, Qiao H, Jiang H, Xu R, Sun X.

Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.

PMID:
19709125
17.

β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.

Huss S, Nehles J, Binot E, Wardelmann E, Mittler J, Kleine MA, Künstlinger H, Hartmann W, Hohenberger P, Merkelbach-Bruse S, Buettner R, Schildhaus HU.

Histopathology. 2013 Jan;62(2):294-304. doi: 10.1111/j.1365-2559.2012.04355.x. Epub 2012 Sep 28.

PMID:
23020601
18.

[The renal protective effect of selective cyclooxygenase-2 inhibitor on obstructive nephropathy].

Zuo Y, Ma J, Gu Y, Yang H, Lin S.

Zhonghua Nei Ke Za Zhi. 2002 Dec;41(12):825-8. Chinese.

PMID:
12654237
19.

Immunohistochemical characteristics of desmoid tumors.

Dubova EA, Sidorenko TV, Shchyogolev AI, Adamyan AA.

Bull Exp Biol Med. 2012 Apr;152(6):743-7. English, Russian.

PMID:
22803179
20.

Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.

Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE, Lev D.

Am J Pathol. 2008 Nov;173(5):1518-27. doi: 10.2353/ajpath.2008.080475. Epub 2008 Oct 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk